Talk:Dacomitinib
Latest comment: 7 years ago by Rod57 in topic Clarify inhibitory effect on normal and various mutated forms of EGFR
This is the talk page for discussing improvements to the Dacomitinib article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Dacomitinib.
|
Improved PFS in NSCLC - ASCO 2017
editCould mention Dacomitinib Sets PFS Record in Phase III NSCLC Trial. 2017 : "...Dacomitinib treatment extended median progression-free survival by 5.5 months versus gefitinib -- to 14.7 months -..." & toxicity issues - Rod57 (talk) 10:05, 9 June 2017 (UTC)
Clarify inhibitory effect on normal and various mutated forms of EGFR
editThe trials seem to be on patients with mutated EGFR but does it also inhibit normal EGFR ? - Rod57 (talk) 10:17, 9 June 2017 (UTC)